Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate

Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate (EDU/OHPH/TCHP), sold under the brand name Trioestrine Retard, is an injectable combination medication of estradiol diundecylate (EDU), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone cyclohexylpropionate (TCHP), an androgen/anabolic steroid.^[1][2][3] It contained 2.25 mg EDU, 100 mg OHPH, and 67.5 mg TCHP in oil solution, was provided as ampoules, and was administered by intramuscular injection.^{[1][2][3][4][5]} The medication was manufactured by Roussel and Théramex and was marketed by 1953.^[6] It is no longer available.^[7][8]

EDU/OHPH/TCHP

Combination of
Estradiol diundecylate	Estrogen
Hydroxyprogesterone heptanoate	Progestogen
Testosterone cyclohexylpropionate	Androgen; Anabolic steroid
Clinical data
Trade names	Trioestrine Retard
Other names	EDU/OHPH/TCHP
Routes of administration	Intramuscular injection

See also

• List of combined sex-hormonal preparations § Estrogens, progestogens, and androgens